Search company, investor...

Metamark Genetics


Series B - II | Alive

Total Raised


Last Raised

$13M | 10 yrs ago

About Metamark Genetics

Metamark Genetics is a privately-held biotechnology company founded to develop novel, function-based prognostic and diagnostic tests aimed at improving urological cancer care. Metamark is a provider of specialty urological pathology testing services with the first fully integrated clinical model for the prostate cancer care pathway.

Headquarters Location

283 Bear Hill Road

Waltham, Massachusetts, 02451,

United States


Missing: Metamark Genetics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Metamark Genetics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Metamark Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metamark Genetics is included in 3 Expert Collections, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Metamark Genetics Patents

Metamark Genetics has filed 2 patents.

The 3 most popular patent topics include:

  • Glycoproteins
  • Gynaecological cancer
  • Oncology
patents chart

Application Date

Grant Date


Related Topics



Oncology, Prostate cancer, Cancer treatments, Radiation therapy, Rare cancers


Application Date


Grant Date


Related Topics

Oncology, Prostate cancer, Cancer treatments, Radiation therapy, Rare cancers



Latest Metamark Genetics News

Prostate Cancer Diagnostics Market will achieve USD 11.16 billion by 2030 : GreyViews

Jan 17, 2023

Major Players MDXHEALTH, F. Hoffmann-La Roche Ltd, Genomic Health, Inc., Siemens Healthcare GmbH, Abbott, Metamark Genetics, Inc., HUMASIS, FUJIREBIO, OPKO Health, Inc., bioMérieux, Inc., Siemens Healthcare GmbH, Diasorin S.P.A. among others. Segmentation Analysis Preliminary is expected to be the fastest-growing segment in 2022. The test type segment includes confirmatory and preliminary. The preliminary segment is expected to witness the highest growth rate during the forecast period. As prostate cancer is on the rise over the forecast period in the region, it is boosting the demand for the preliminary test segment. The American Institute for Cancer Research has noted that PSA screening has helped diagnose and treat early cancers, leading to an increase in survival rates. PSA tests detect small, unrecognized tumours which may or may not progress to advanced stages. Hospital-associated laboratories are expected to be the fastest-growing segment in 2022. The end-user segment includes cancer research institutes, hospital-associated laboratories and independent diagnostics laboratories. The hospital-associated laboratories segment is expected to witness the highest growth rate during the forecast period. In the global prostate cancer diagnostics market, hospital associated laboratories are expected to take the majority share during the forecast period because of an increase in prostate cancer cases. In the forecast period, the market growth will be driven by rising disease prevalence and technological advancements. Regional Analysis            The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the biomarkers market include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North American region witnessed a major share. It is expected that North America will dominate the market due to factors such as increased prostate cancer prevalence, increased awareness, and the increasing number of research and development companies in this region. Prostate cancer cases are rising, creating huge opportunities for market players, and many are developing new and effective treatments. Country Analysis Germany Germany's prostate cancer diagnostics market size was valued at USD 0.83 billion in 2022 and is expected to reach USD 0.85 billion by 2030, at a CAGR of 13.5% from 2023 to 2030. Innovative products, growing awareness and government initiatives are all contributing to the growth of the prostate cancer diagnostics market. China China’s prostate cancer diagnostics market size was valued at USD 0.33 billion in 2022 and is expected to reach USD 0.92 billion by 2030, at a CAGR of 13.7% from 2023 to 2030. As China has a large population and therefore has more tests per capita than any other country in the region, China is expected to dominate the Asia-Pacific prostate cancer diagnostics market. India India's prostate cancer diagnostics market size was valued at USD 0.25 billion in 2022 and is expected to reach USD 0.69 billion by 2030, at a CAGR of 13.6% from 2023 to 2030. The availability of a wide range of products, adjustments in consumption patterns, improved lifestyles, and an increase in personal care spending are anticipated to contribute to the growth of the nail industry in the future. The popularity of nail polish and nail art has increased in the country due to a growing party culture as well as a variety of festivals and functions. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of this market is mainly driven owing to the increase due of the rising cases of cancer and cardiovascular diseases, propelling the growth of the market across the countries. Buy Now Full Report @ Contact Us

Metamark Genetics Frequently Asked Questions (FAQ)

  • Where is Metamark Genetics's headquarters?

    Metamark Genetics's headquarters is located at 283 Bear Hill Road, Waltham.

  • What is Metamark Genetics's latest funding round?

    Metamark Genetics's latest funding round is Series B - II.

  • How much did Metamark Genetics raise?

    Metamark Genetics raised a total of $37.92M.

  • Who are the investors of Metamark Genetics?

    Investors of Metamark Genetics include Massachusetts Life Sciences Center.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.